Neopharmed Gentili S.p.A. acquires BioCryst Ireland Limited for USD 250,000,000 (2025)

Deal facts

Buyer: Neopharmed Gentili S.p.A.
Target: BioCryst Ireland Limited
Deal value: USD 250,000,000
Announced: 27 June 2025
Status: Completed
Sector: Healthcare
Country: Ireland
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

1 Oct 2025CompletedClosed
Neopharmed Gentili S.p.A. completes acquisition of BioCryst Ireland Limited
Introductory Note As previously announced, on June 27, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ” or the “ Company ”), and BioCryst Ireland Limited (“ BioCryst Ireland ”), a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of the Company, entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with Neopharmed
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of BioCryst Ireland Limited by Neopharmed Gentili S.p.A. for 250 million USD. This cross-border transaction within the healthcare sector moves assets from Ireland to Italy and settles entirely in cash. The deal type is recorded as an asset sale, which often signals a strategic focus on specific intellectual property or product lines rather than a full corporate takeover. For the SME founder, this structure highlights how buyers can isolate valuable commercial rights without inheriting the entire corporate history of the target.

The use of cash consideration removes the immediate uncertainty of share price fluctuations for the seller, yet the asset sale mechanics introduce distinct regulatory layers. A transaction of this size between EU jurisdictions will have triggered scrutiny under EU competition rules, requiring clearance from the European Commission before the deal could close. The buyer likely had to navigate change-of-control covenants within existing supply or licensing agreements to ensure the transfer of these specific assets did not breach prior commitments. These are not mere formalities but critical gates that determine whether a deal proceeds or stalls.

We believe this deal demonstrates that even in a complex regulatory environment, cash remains a powerful tool to unlock value for niche players. The clean exit achieved here suggests that buyers are willing to pay a premium for certainty when the asset base is strong and the regulatory path is clear. The SME founder reading this should note that defining the scope of the sale early can streamline the clearance process and make the target more attractive to international buyers seeking specific capabilities.

Do not wait until you have a term sheet to map out which assets are free from third-party restrictions. This week, review your key licensing agreements and identify any clauses that require third-party consent for a change of control or an asset transfer.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More asset sale deals More from Neopharmed Gentili S.p.A.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

14 October 2026Firm intentionHealthcare

Laboratory Corporation of America Holdings to acquire BioReference Health, LLC

Laboratory Corporation of America Holdings has agreed to acquire BioReference Health, LLC in a transaction valued at 722 million US dollars. The deal, announced on 14 Oc…

Buyer: Laboratory Corporation of America Holdings
Target: BioReference Health, LLC
Deal value: USD 722,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

14 October 2026CompletedHealthcare

Silo Pharma, Inc. to acquire Larry King

Silo Pharma, Inc. has completed the acquisition of assets from Larry King. The transaction, which was announced on 14 October 2026, was finalized on 13 October 2026. Bot…

Buyer: Silo Pharma, Inc.
Target: Larry King
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

2 October 2026Firm intentionHealthcare

Silo Pharma, Inc. to acquire Norsight Consulting Inc.

Silo Pharma, Inc. has agreed to acquire assets from Norsight Consulting Inc. in a transaction announced on 2 October 2026. Both companies are based in the United States…

Buyer: Silo Pharma, Inc.
Target: Norsight Consulting Inc.
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

1 October 2026CompletedHealthcare

JOINT Corp to acquire The Joint Franchises San Antonio, LLC, The Joint Franchises DFW, LLC, The Joint Franchises Houston, LLC, The Joint Franchises Austin, LLC, and The Joint Franchises Texas, Ltd.

JOINT Corp has agreed to acquire a portfolio of five Texas-based entities from The Joint franchise network. The transaction, announced and completed on 1 October 2026, i…

Buyer: JOINT Corp
Target: The Joint Franchises San Antonio, LLC, The Joint Franchises DFW, LLC, The Joint Franchises Houston, LLC, The Joint Franchises Austin, LLC, and The Joint Franchises Texas, Ltd.
Deal value: USD 8,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

30 September 2026Firm intentionHealthcare

Element Biosystems, LLC to acquire Standard BioTools Inc.

Element Biosystems, LLC has agreed to acquire Standard BioTools Inc. in a cash asset sale. The transaction was announced on 30 September 2026 and is valued at five milli…

Buyer: Element Biosystems, LLC
Target: Standard BioTools Inc.
Deal value: USD 5,500,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

Buyer history